Drug Profile
Porcine spinal cord cells
Latest Information Update: 29 Jun 2017
Price :
$50
*
At a glance
- Originator GenVec
- Class
- Mechanism of Action Tissue replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Spinal cord injuries
Most Recent Events
- 16 Jun 2017 GenVec was acquired by Intrexon Corporation
- 30 Jul 2004 Discontinued - Phase-I for Spinal cord injuries in USA (Intraspinal)
- 26 Aug 2003 Diacrin has been acquired by, and merged into, GenVec